Nucleic Acids ResearchMolecular BiologyPeer-reviewed journal article
Modulating NLRP3 splicing with antisense oligonucleotides to control pathological inflammation
Roni KleiniD, Janset OnyuruiD, Jessica L. CentaiD, Estela M. Viera, Fox J. Duelli, Christopher D. PutnamiD, Hal M. HoffmaniD, Michelle L. HastingsiD
Abstract
Inflammation has an essential role in healing. However, over-active inflammation disrupts normal cellular functions and can be life-threatening when not resolved. The NLR family pyrin domain-containing 3 (NLRP3) inflammasome, a component of the innate immune system, is an intracellular multiprotein complex that senses stress-associated signals, and, for this reason is a promising therapeutic target for treating unresolved, pathogenic inflammation. Alternative splicing of NLRP3 RNA has been suggested as a regulatory mechanism for inflammasome activation, as some spliced isoforms encode NLRP3 proteins with compromised function. Here, we take advantage of this natural regulatory mechanism and devise a way to control pathogenic inflammation using splice-switching antisense oligonucleotides (ASOs). To identify and induce NLRP3 isoforms lacking inflammatory activity, we tested a series of ASOs, each targeting a different exon, to determine the most effective strategy for down-regulating NLRP3. We identify several ASOs that modulate NLRP3 splicing, reduce NLRP3 protein, and decrease inflammasome signaling in vitro. The most effective ASO suppresses systemic inflammation in vivo in mouse models of acute inflammation and cryopyrin-associated periodic syndrome (CAPS). Overall, these results demonstrate how ASOs can be used to systematically engineer proteins with modified functions and treat pathological inflammation in mice by reducing functional NLRP3.
- Citations
- 6
- FWCI
- 1.80
- Field percentile
- top 14%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of a Potent and Selective Inhibitor of Human NLRP3 with a Novel Binding Modality and Mechanism of Action
Kevin Wilhelmsen, Aditi Deshpande, … Rebecca C. Coll·The Journal of Experimental MedicinePeer-reviewed·Jul 24, 2025
- Minoxidil hydrochloride impedes NLRP3 inflammasome activation via upregulation of AMPK-mediated autophagy
Sukhleen Kaur, Mehboob Ali, … Ajay Kumar·bioRxiv·Oct 16, 2026
- MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition
L. Vande Walle, I. B. Stowe, … M. Lamkanfi·bioRxiv·May 11, 2019
- Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation.
- A detailed Molecular Network Map and Model of the NLRP3 Inflammasome
M. Krantz, D. Eklund, … A. Hedbrant·bioRxiv·May 31, 2023
- FDA-approved drug library screen identifies antidepressants, antimicrobials, anti-COPD, and anti-CVD agents as blockers of NLRP3 inflammasome and sepsis in a sex-dependent manner.
Kara Timinski, Ashutosh Prince, … Kailash Gulshan·bioRxiv·Jul 29, 2026